Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study Authors: Chao Wu, Xiao Ma, Yong-jun Wang, Tie-jun Liu, Xin-yuan Zhang, Hong-zhong Jin Published: 2026 ABSTRACT BackgroundHidradenitis suppurativa (HS) is a chronic inflammatory skin disease in which interleukin-17A (IL-17A) is an important therapeutic target. However, prospective real-world data on secukinumab (IL-17A inhibitor) safety and efficacy in Chinese patients with HS remain limited.ObjectiveTo evaluate the 16-week efficacy and safety of secukinumab in Chinese patients with moderate-to-severe HS and explore potential treatment response predictors.MethodsThis single-center, prospective, real-world cohort study included 31 patients with moderate-to-severe HS. The patients received subcutaneous secukinumab 300 mg weekly for 5 weeks, followed by administration either every 2 (1 patient [3.23%]) or 4 (30 patients [96.77%]) weeks. Concomitant therapies were allowed when clinically indicated. The primary endpoint was Hidradenitis Suppurativa Clinical Response (HiSCR) at week 16. Secondary endpoints included changes in inflammatory nodule, abscess, and draining tunnel counts, International Hidradenitis Suppurativa Severity Score System (IHS4), Numeric Rating Scale (NRS) for pain, Dermatology Life Quality Index (DLQI), adverse events, and exploratory predictors of HiSCR.ResultsThe cohort was predominantly male (77.42%). Ten patients (32.26%) were classified as Hurley stage II and 21 (67.74%) as Hurley stage III. During treatment, 74.19% of patients received concomitant therapies. At week 16, HiSCR was achieved by 17/31 patients (54.84%). Inflammatory nodule counts, draining tunnel counts, IHS4, and DLQI significantly decreased. In the adjusted multivariate logistic regression model, after adjustment for prior biologic use, decreased high-density lipoprotein cholesterol, and dyslipidemia, elevated triglyceride was independently associated with HiSCR achievement (β= 3.246, p = 0.037). Adverse events were mild, including acne in two patients (6.45%), facial allergic dermatitis in one (3.23%), fever in two (6.45%), and fatigue in one (3.23%). None discontinued treatment because of adverse events.ConclusionsSecukinumab demonstrated meaningful 16-week efficacy and favorable safety in Chinese patients with moderate-to-severe HS. Elevated triglyceride was associated with treatment response in this exploratory analysis; however, further validation in larger cohorts is required. Introduction Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent inflammatory skin disease that primarily affects intertriginous areas rich in apocrine-bearing follicles, including the axillary, inguinal, perineal, perianal, gluteal, and inframammary regions. Epidemiological estimates vary substantially by study design, geographic region, race, and case definition. However, the reported prevalence of HS ranges from very low registry-based estimates to more than 4%, whereas large database studies have commonly reported a prevalence of approximately 0.1% and an annual incidence of around 11.4 per 100,000 persons.1–3 In China, a nationwide cross-sectional epidemiological study reported a prevalence of 33.49 per 100,000 dermatology clinic visitors, suggesting that HS is relatively uncommon in the Chinese clinical setting and may be under-recognized.4 These epidemiological features partly explain the limited sample sizes of Chinese prospective studies and highlight the need for region-specific real-world evidence. Clinically, HS is characterized by painful inflammatory nodules, abscesses, draining tunnels, recurrent suppuration, malodorous discharge, and irreversible scarring.1,5 HS is increasingly regarded as a systemic inflammatory disorder rather than a purely local follicular disease. Patients frequently present with obesity, smoking exposure, metabolic syndrome, diabetes mellitus, dyslipidemia, cardiovascular risk, inflammatory bowel disease, arthritis, and psychiatric comorbidities.1,6 Lipid abnormalities are particularly relevant, and previous studies have consistently reported higher triglyceride and lower high-density lipoprotein cholesterol (HDL-C) in patients with HS than in healthy control individuals.7–9 Moreover, a case–control study showed increased insulin resistance, metabolic syndrome, fasting glucose, insulin, and triglycerides in patients with HS.10 The pathogenesis of HS is multifactorial. Follicular occlusion and rupture initiate innate immune activation, bacterial biofilm formation, neutrophil recruitment, keratinocyte dysregulation, fibrosis, and tunnel formation. Cytokine networks involving tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-23, IL-36, and IL-17 amplify local and systemic inflammation.1,5,11 Among these pathways, IL-17A promotes neutrophil-rich inflammation, induces keratinocyte-derived antimicrobial peptides and inflammatory mediators, supporting the development of IL-17-targeted therapies for moderate-to-severe HS.11,12 The response to conventional systemic therapy is often incomplete, as these treatments may provide insufficient symptom control, fail to fully suppress recurrent inflammation, or have limited effects on established draining tunnels and scarring.11,12 Adalimumab, a TNF-α inhibitor, was the first approved biologic for moderate-to-severe HS, but many patients fail to achieve durable control, and flares may still occur during treatment.11,13 Recent expert recommendations have therefore shifted toward earlier biologic or small-molecule therapy in selected patients, especially those with antibiotic contraindications, rapid disease progression, frequent flares, Hurley II/III disease with draining tunnels, severe Hurley I disease according to the International Hidradenitis Suppurativa Severity Score System (IHS4), multisite disease, anogenital involvement, syndromic HS, or inflammatory comorbidities.14 Network meta-analysis evidence also supports the expanding role of approved biologics in moderate-to-severe HS, although direct head-to-head comparisons are scarce.15 Secukinumab is a fully human monoclonal antibody that selectively inhibits IL-17A. In the Phase 3 SUNSHINE and SUNRISE trials, secukinumab improved the clinical signs and symptoms of moderate-to-severe HS compared with placebo at week 16, with the response sustained through week 52.16 However, these randomized controlled trials mainly evaluated secukinumab under controlled trial conditions, whereas patients in routine clinical practice often have more complex disease characteristics, longer disease duration, greater tunnel burden, previous biologic exposure, and concomitant use of systemic antibiotics, retinoids, intralesional corticosteroids, drainage procedures, or surgery. Therefore, the effectiveness and safety observed in real-world secukinumab-containing treatment regimens may differ from those reported in trials of secukinumab monotherapy. Subsequent real-world studies reported meaningful short-term and longer-term effectiveness, with response heterogeneity related to sex, body mass index (BMI), therapeutic burden, biologic exposure, disease stage, tunnels, and timing of biologic initiation.17–24 Although data from the Asian population are emerging, these data remain limited. Recent studies in China have largely focused on secukinumab combined with surgical intervention in patients with severe or refractory HS.25–27 However, a substantial proportion of patients still fail to achieve Hidradenitis Suppurativa Clinical Response (HiSCR).16 Prospective real-world evidence in Chinese patients remains particularly limited. Given potential differences in disease characteristics, treatment patterns, and healthcare settings, Chinese real-world data are important for evaluating the effectiveness and safety of secukinumab-containing treatment strategies in routine clinical practice. The present single-center, prospective, real-world cohort study evaluated the 16-week effectiveness and safety of secukinumab-containing treatment regimens in Chinese patients with moderate-to-severe HS. As a secondary exploratory objective, we assessed baseline clinical and laboratory factors associated with HiSCR. The study therefore focuses primarily on practical short-term outcomes in a Chinese cohort with advanced disease and clinically indicated concomitant therapy. Materials and Methods Study Cohort This study was a prospective, observational cohort study conducted at Peking Union Medical College Hospital. This study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Patients were eligible if they met the following criteria: 1) aged 12–70 years (male or female); 2) a definitive diagnosis of moderate-to-severe HS, defined as Hurley stage II or III disease and/or moderate-to-severe disease according to IHS4; and 3) ability of the patient or a family member to understand the study protocol and willingness to participate, with provision of written informed consent. The exclusion criteria were 1) treatment with systemic biological immunomodulators within three months or five half-lives prior to enrollment; 2) uncertain diagnosis of the primary disease; 3) contraindications to IL-17A inhibitor therapy; 4) concomitant active skin diseases that could affect disease assessment; 5) pregnancy, lactation, or planned pregnancy within one year; and 6) a history of severe uncontrolled systemic disease, autoimmune disease, malignant tumor, or infection. Because HS is relatively uncommon in our clinical setting, eligible patients were consecutively recruited throughout the predefined study period. The sample size was therefore determined by the number of eligible patients available during the recruitment period rather than by a formal a priori sample-size calculation. A total of 31 patients were enrolled and included in the analysis. The patients received subcutaneous secukinumab 300 mg weekly for the first 5 weeks, followed by maintenance treatment every 4 weeks in 30 patients (96.77%). One patient (3.23%), after discussion of the available maintenance regimens and based on personal treatment preference and financial affordability, elected to receive secukinumab 300 mg every 2 weeks in an effort to achieve more intensive disease control. As this was a real-world study, concomitant therapies were permitted when clinically indicated, including systemic antibiotics; systemic retinoids, such as acitretin or isotretinoin; intralesional corticosteroid injections; incision and drainage; and limited surgical procedures. All concomitant medications and procedures were documented throughout the study and considered when interpreting treatment outcomes. Evaluation Parameters Baseline demographic and clinical characteristics, including sex, age, disease duration, smoking status, height, weight, BMI, treatment history, family history, and comorbidities, were collected through medical record review and electronic questionnaires. HS severity was assessed using the Hurley staging system, the IHS4,28 and the NRS for skin pain. HiSCR was defined as a reduction of ≥50% in the total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining tunnel count relative to baseline.29 Elevated triglyceride, decreased HDL-C, and dyslipidemia were defined according to the Chinese guideline for lipid management (2023).30 Elevated triglyceride was defined as ≥2.3 mmol/L, decreased HDL-C as <1.0 mmol/L, elevated total cholesterol (TC) as ≥5.2 mmol/L, and elevated low-density lipoprotein cholesterol (LDL-C) as ≥3.4 mmol/L. Dyslipidemia was defined as the presence of at least one abnormal lipid parameter, including elevated triglyceride, decreased HDL-C, elevated TC, or elevated LDL-C.30 All samples were collected after an overnight fast of at least 12 h. Lipid parameters, including TG, TC, HDL-C, and LDL-C, were collected and analyzed. The TC, TG, HDL-C, and LDL-C reagents were produced by SEKISUI (SEKISUI CHEMICAL CO., LTD, Japan), and the analytes were measured by Beckman Coulter AU5800 instrument (Beckman Coulter, Inc., Brea, CA, USA). The DLQI was used to evaluate changes in quality of life. Adverse events recorded during the treatment period were collected. Ethics This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Peking Union Medical College Hospital (I-25PJ3021). The study was registered in the Chinese Clinical Trial Registry (ChiCTR2600120670) and at ClinicalTrials.gov (NCT07109765). All participants or their legal representatives provided written informed consent prior to participation. For participants younger than 18 years, written informed consent was obtained from their parents or legal guardians, and assent was obtained from the participants when appropriate. The informed consent included permission for the publication of anonymized clinical information, images, and responses or direct quotes, where applicable. Measures were implemented to ensure the confidentiality and anonymity of participants’ personal information. Statistical Analysis Given the limited sample size, descriptive statistics were used to summarize clinical efficacy measures and adverse events. Continuous variables are presented as the mean ± standard deviation, and categorical variables as counts and percentages. Paired continuous variables between baseline and week 16 were compared using the paired t-test or Wilcoxon signed-rank test, as appropriate. For paired endpoints, p values were calculated from within-participant changes; statistical significance therefore depends on the distribution and variability of those paired changes rather than only on the difference between group means. Between-group continuous variables were compared using Student’s t-test or the Mann–Whitney U-test, and categorical variables using the χ2-test or Fisher’s exact test, as appropriate. For the exploratory analysis of factors associated with HiSCR achievement, variables with clinical relevance or potential statistical association in univariate analysis were considered for multivariable logistic regression. Given the limited sample size and number of outcome events, the final adjusted model included elevated triglyceride, prior biologic medication use, decreased HDL-C, and dyslipidemia. Highly overlapping variables were assessed before model construction, and multicollinearity was evaluated using variance inflation factors; no substantial multicollinearity was observed among retained variables. Secondary-endpoint and predictor analyses were exploratory, and no adjustment for multiple comparisons was applied; p values should therefore be interpreted cautiously. Statistical significance was defined as p < 0.05. Analyses were performed using SPSS Statistics 31.0 (IBM Corp., Armonk, NY, USA). Results Baseline Demographic and Clinical Characteristics Overall, 31 patients with moderate-to-severe HS were enrolled. The baseline demographic and clinical characteristics are summarized in Table 1. The mean age was 26.52 ± 10.24 years, the mean age at HS onset was 19.06 ± 7.53 years, and the mean disease duration was 7.45 ± 5.86 years, with a median duration of 5.0 years. The cohort was predominantly male (24/31 [77.42%]), while female patients accounted for 7/31 (22.58%). The mean BMI was 28.60 ± 4.07 kg/m2. A positive family history of HS was recorded in 4/31 patients (12.90%), and 14/31 participants (45.16%) were current smokers, with a mean smoking intensity of 12.3 ± 8.4 cigarettes/day.Table 1Baseline Features of the PatientsCharacteristicsPatients (n = 31)Age (mean±SD), years26.52±10.24Age onset (mean±SD), years19.06±7.53Disease duration (mean±SD, median), years7.45±5.86, 5.0Sex, n (%) Male24 (77.42) Female7 (22.58)BMI (mean±SD), kg/m228.60±4.07BMI categories among adult participants (n=30), n (%) Normal weight (18.5–24.9 kg/m2)8 (26.7) Overweight (25.0–29.9 kg/m2)8 (26.7) Obesity (≥30.0 kg/m2)14 (46.7)Family history of HS, n (%) No27 (87.10) Yes4 (12.90)Smoking, n (%) No17 (54.84) Yes14 (45.16) Smoking intensity (eg, cigarettes/day)12.3 ± 8.4Comorbidities, n (%) Obesity9 (29.03) Diabetes mellitus5 (16.13) Abnormal liver function2 (6.45) Anemia2 (6.45) Mental disorders1 (3.23) Inflammatory bowel disease1 (3.23) Coronary heart disease1 (3.23) Hyperuricemia1 (3.23) Fatty liver1 (3.23) Hypertension1 (3.23) Asthma1 (3.23)Number of previous systemic treatments, n (%) Nonbiologic drugs24 (77.4) Biologic drugs7 (22.6)Hurley stage, n (%) I0 (0) II10 (32.26) III21 (67.74)Anatomic regions (mean±SD)3.58±1.41Affected lesion sites/distribution, n (%) Axillae31 (100.0%) Inguinal region24 (77.42%) Gluteal region16 (51.61%) Scalp12 (38.71%) Nuchal region12 (38.71%) Genital region8 (25.81%)Inflammatory nodules (mean±SD)8.32±7.52Abscesses (mean±SD)2.42±2.81Inflamed or draining tunnels (mean±SD)2.81±2.43Baseline IHS4 (mean±SD)24.39±18.64Baseline pain NRS (mean±SD)4.52±1.90Baseline DLQI (mean±SD)15.97±6.44Combined treatment, n (%) No8 (25.81) Systemic antibiotic22 (70.97) Systemic retinoids7 (22.58)Combined surgery, n (%) Yes2 (6.45) No29 (93.55)Notes: Data are expressed as relative (absolute) frequency and mean (standard deviation, SD), BMI categories were defined using adult BMI cutoffs for participants aged ≥18 years; the single participant younger than 18 years was not included in this categorical analysis.Abbreviations: HS, hidradenitis suppurativa; BMI, body mass index; NRS, Numeric Rating Scale; IHS4, International Hidradenitis Suppurativa Severity Scoring System; DLQI, The Dermatology Life Quality Index. Table 1Baseline Features of the PatientsCharacteristicsPatients (n = 31)Age (mean±SD), years26.52±10.24Age onset (mean±SD), years19.06±7.53Disease duration (mean±SD, median), years7.45±5.86, 5.0Sex, n (%) Male24 (77.42) Female7 (22.58)BMI (mean±SD), kg/m228.60±4.07BMI categories among adult participants (n=30), n (%) Normal weight (18.5–24.9 kg/m2)8 (26.7) Overweight (25.0–29.9 kg/m2)8 (26.7) Obesity (≥30.0 kg/m2)14 (46.7)Family history of HS, n (%) No27 (87.10) Yes4 (12.90)Smoking, n (%) No17 (54.84) Yes14 (45.16) Smoking intensity (eg, cigarettes/day)12.3 ± 8.4Comorbidities, n (%) Obesity9 (29.03) Diabetes mellitus5 (16.13) Abnormal liver function2 (6.45) Anemia2 (6.45) Mental disorders1 (3.23) Inflammatory bowel disease1 (3.23) Coronary heart disease1 (3.23) Hyperuricemia1 (3.23) Fatty liver1 (3.23) Hypertension1 (3.23) Asthma1 (3.23)Number of previous systemic treatments, n (%) Nonbiologic drugs24 (77.4) Biologic drugs7 (22.6)Hurley stage, n (%) I0 (0) II10 (32.26) III21 (67.74)Anatomic regions (mean±SD)3.58±1.41Affected lesion sites/distribution, n (%) Axillae31 (100.0%) Inguinal region24 (77.42%) Gluteal region16 (51.61%) Scalp12 (38.71%) Nuchal region12 (38.71%) Genital region8 (25.81%)Inflammatory nodules (mean±SD)8.32±7.52Abscesses (mean±SD)2.42±2.81Inflamed or draining tunnels (mean±SD)2.81±2.43Baseline IHS4 (mean±SD)24.39±18.64Baseline pain NRS (mean±SD)4.52±1.90Baseline DLQI (mean±SD)15.97±6.44Combined treatment, n (%) No8 (25.81) Systemic antibiotic22 (70.97) Systemic retinoids7 (22.58)Combined surgery, n (%) Yes2 (6.45) No29 (93.55)Notes: Data are expressed as relative (absolute) frequency and mean (standard deviation, SD), BMI categories were defined using adult BMI cutoffs for participants aged ≥18 years; the single participant younger than 18 years was not included in this categorical analysis.Abbreviations: HS, hidradenitis suppurativa; BMI, body mass index; NRS, Numeric Rating Scale; IHS4, International Hidradenitis Suppurativa Severity Scoring System; DLQI, The Dermatology Life Quality Index. Baseline Features of the Patients Notes: Data are expressed as relative (absolute) frequency and mean (standard deviation, SD), BMI categories were defined using adult BMI cutoffs for participants aged ≥18 years; the single participant younger than 18 years was not included in this categorical analysis. Abbreviations: HS, hidradenitis suppurativa; BMI, body mass index; NRS, Numeric Rating Scale; IHS4, International Hidradenitis Suppurativa Severity Scoring System; DLQI, The Dermatology Life Quality Index. Obesity was the most common comorbidity (9/31 [29.03%]), followed by diabetes mellitus (16.13%). Regarding prior treatment history, 77.4% of the patients had received non-biologic systemic therapies, and 22.6% had previous exposure to biologic agents. No patient was classified as Hurley stage I, 10/31 (32.26%) were classified as Hurley stage II, and the majority (21/31 [67.74%]) were classified as Hurley stage III. The mean number of affected anatomical regions per patient was 3.58 ± 1.41. The axillae were involved in all patients (31/31, 100.0%), followed by the inguinal region (24/31, 77.42%), gluteal region (16/31, 51.61%), scalp (12/31, 38.71%), nuchal region (12/31, 38.71%), and genital region (8/31, 25.81%). At baseline, the mean IHS4 score was 24.39 ± 18.64, the mean NRS score for pain was 4.52 ± 1.90, and the mean DLQI was 15.97 ± 6.44. Regarding concomitant medications, 22/31 patients (70.97%) received systemic antibiotics, 7/31 (22.58%) received systemic retinoids, and 8/31 (25.81%) received no additional combined therapy. In addition, 2/31 patients (6.45%) underwent concurrent surgical intervention. These concomitant therapies reflect real-world clinical practice and should be considered when interpreting the observed efficacy of secukinumab treatment. Clinical Response and Safety At week 16 of secukinumab treatment, improvements were observed in clinical lesions, disease severity, and quality of life (Table 2 and Figure 1A–G). Inflammatory nodules decreased from 8.32 ± 7.52 at baseline to 4.95 ± 4.99 at week 16, corresponding to a 40.5% reduction from baseline (p < 0.001; Figure 1B). Abscess counts decreased by 33.1%, from 2.42 ± 2.81 to 1.62 ± 2.03, but the paired change was not statistically significant (p = 0.284; Figure 1C). Inflamed or draining tunnel counts decreased by 13.5%, from 2.81 ± 2.43 to 2.43 ± 2.11 (p = 0.015; Figure 1D). Because these comparisons were based on paired within-patient changes, statistical significance depended on the distribution and variability of individual changes rather than on the magnitude of the difference between the group means alone.Table 2Clinical Response at Week 16BaselineWeek16p valueChange in GroupMean from Baseline, %Inflammatory nodules (mean±SD)8.32±7.524.95±4.99<0.001−40.5Abscesses (mean±SD)2.42±2.811.62±2.030.284−33.1Inflamed or draining tunnels (mean±SD)2.81±2.432.43±2.110.015−13.5IHS4 (mean±SD)24.39±18.6417.90±12.35<0.001−26.6Pain NRS (mean±SD)4.52±1.903.24±2.210.064−28.3DLQI (mean±SD)15.97±6.4410.64±8.870.004−33.4HiSCR, n (%)—17/31 (54.8%)—Notes: Data are expressed as relative (absolute) frequency and mean (standard deviation, SD). Percentage change was calculated from the reported group means as (week 16 − baseline)/baseline × 100.Abbreviations: IHS4, International; HS, Severity Scoring System; NRS, Numeric Rating Scale; HiSCR, Hidradenitis Suppurativa Clinical Response. Figure 1Clinical response at week 16 in patients with hidradenitis suppurativa treated with secukinumab. (A) The Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 was 54.8%. (B) Inflammatory nodules decreased from 8.32 ± 7.52 at baseline to 4.95 ± 4.99 at week 16 (P < 0.001). (C) Abscesses decreased from 2.42 ± 2.81 to 1.62 ± 2.03 (P = 0.284). (D) Inflamed or draining tunnels decreased from 2.81 ± 2.43 to 2.43 ± 2.11 (P = 0.015). (E) International Hidradenitis Suppurativa Severity Score System (IHS4) decreased from 24.39 ± 18.64 to 17.90 ± 12.35 (P < 0.001). (F) Pain Numeric Rating Scale (NRS) decreased from 4.52 ± 1.90 to 3.24 ± 2.21 (P = 0.064). (G) Dermatology Life Quality Index (DLQI) decreased from 15.97 ± 6.44 to 10.64 ± 8.87 (P = 0.004). Data are presented as mean ± standard deviation (SD). n = 31.Multiple bar charts showing clinical response at week 16 for HiSCR and other hidradenitis measures.Image A: Bar chart titled ′HiSCR response′ shows 54.8% patient response at Week 16. Image B: ′Inflammatory nodules′ chart compares Baseline (8.32 plus or minus 7.52) and Week 16 (4.95 plus or minus 4.99), with P<0.001. Image C: ′Abscesses′ chart shows Baseline (2.42 plus or minus 2.81) and Week 16 (1.62 plus or minus 2.03), P=0.284. Image D: ′Inflamed or draining tunnels′ chart shows Baseline (2.81 plus or minus 2.43) and Week 16 (2.43 plus or minus 2.11), P=0.015. Image E: ′IHS4′ chart shows Baseline (24.39 plus or minus 18.64) and Week 16 (17.90 plus or minus 12.35), P<0.001. Image F: ′Pain NRS′ chart shows Baseline (4.52 plus or minus 1.90) and Week 16 (3.24 plus or minus 2.21), P=0.064. Image G: ′DLQI′ chart shows Baseline (15.97 plus or minus 6.44) and Week 16 (10.64 plus or minus 8.87), P=0.004. Table 2Clinical Response at Week 16BaselineWeek16p valueChange in GroupMean from Baseline, %Inflammatory nodules (mean±SD)8.32±7.524.95±4.99<0.001−40.5Abscesses (mean±SD)2.42±2.811.62±2.030.284−33.1Inflamed or draining tunnels (mean±SD)2.81±2.432.43±2.110.015−13.5IHS4 (mean±SD)24.39±18.6417.90±12.35<0.001−26.6Pain NRS (mean±SD)4.52±1.903.24±2.210.064−28.3DLQI (mean±SD)15.97±6.4410.64±8.870.004−33.4HiSCR, n (%)—17/31 (54.8%)—Notes: Data are expressed as relative (absolute) frequency and mean (standard deviation, SD). Percentage change was calculated from the reported group means as (week 16 − baseline)/baseline × 100.Abbreviations: IHS4, International; HS, Severity Scoring System; NRS, Numeric Rating Scale; HiSCR, Hidradenitis Suppurativa Clinical Response. Clinical Response at Week 16 Notes: Data are expressed as relative (absolute) frequency and mean (standard deviation, SD). Percentage change was calculated from the reported group means as (week 16 − baseline)/baseline × 100. Abbreviations: IHS4, International; HS, Severity Scoring System; NRS, Numeric Rating Scale; HiSCR, Hidradenitis Suppurativa Clinical Response. Clinical response at week 16 in patients with hidradenitis suppurativa treated with secukinumab. (A) The Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 was 54.8%. (B) Inflammatory nodules decreased from 8.32 ± 7.52 at baseline to 4.95 ± 4.99 at week 16 (P < 0.001). (C) Abscesses decreased from 2.42 ± 2.81 to 1.62 ± 2.03 (P = 0.284). (D) Inflamed or draining tunnels decreased from 2.81 ± 2.43 to 2.43 ± 2.11 (P = 0.015). (E) International Hidradenitis Suppurativa Severity Score System (IHS4) decreased from 24.39 ± 18.64 to 17.90 ± 12.35 (P < 0.001). (F) Pain Numeric Rating Scale (NRS) decreased from 4.52 ± 1.90 to 3.24 ± 2.21 (P = 0.064). (G) Dermatology Life Quality Index (DLQI) decreased from 15.97 ± 6.44 to 10.64 ± 8.87 (P = 0.004). Data are presented as mean ± standard deviation (SD). n = 31. The mean IHS4 score decreased by 26.6%, from 24.39 ± 18.64 at baseline to 17.90 ± 12.35 at week 16 (p < 0.001; Figure 1E). The pain NRS decreased from 4.52 ± 1.90 to 3.24 ± 2.21, corresponding to a 28.3% decrease calculated from group means, although the paired change did not reach statistical significance (p = 0.064; Figure 1F). The DLQI decreased by 33.4%, from 15.97 ± 6.44 to 10.64 ± 8.87 (p = 0.004; Figure 1G). Overall, 17/31 patients (54.8%) achieved HiSCR at week 16 (Figure 1A). Representative clinical responses are shown in Figures 2A–F and 3A–C.Figure 2Clinical response of a 21-year-old male patient with hidradenitis suppurativa to secukinumab. (A–C) Left inguinal abscesses and inflammatory nodules at baseline (A), week 4 (B), and week 16 (C), showing progressive resolution of inflammation and near-complete regression of inflammatory nodules by week 16. (D–F) Left axillary nodular lesions at baseline (D), week 4 (E), and week 16 (F), showing marked regression after treatment.Six images showing clinical response of a male patient with hidradenitis suppurativa.Figure 3Clinical response of a 20-year-old male patient with hidradenitis suppurativa to secukinumab. Clinical photographs at baseline (A), week 4 (B), and week 16 (C) show gradual improvement of inflammatory nodules, abscesses, and axillary erosions, accompanied by reduced local inflammation after treatment.Three close-up photos of a man′s axilla over time, showing inflammatory nodules, abscesses, and erosions. Clinical response of a 21-year-old male patient with hidradenitis suppurativa to secukinumab. (A–C) Left inguinal abscesses and inflammatory nodules at baseline (A), week 4 (B), and week 16 (C), showing progressive resolution of inflammation and near-complete regression of inflammatory nodules by week 16. (D–F) Left axillary nodular lesions at baseline (D), week 4 (E), and week 16 (F), showing marked regression after treatment. Clinical response of a 20-year-old male patient with hidradenitis suppurativa to secukinumab. Clinical photographs at baseline (A), week 4 (B), and week 16 (C) show gradual improvement of inflammatory nodules, abscesses, and axillary erosions, accompanied by reduced local inflammation after treatment. Regarding safety and treatment discontinuation at week 16, all recorded adverse events were reported as mild (Table 3). Events included acne (2/31 [6.45%]), facial allergic dermatitis (1/31 [3.23%]), fever (2/31 [6.45%]), and fatigue (1/31 [3.23%]). No patient discontinued secukinumab because of adverse events. Treatment discontinuation occurred in 5/31 patients (16.13%) after week 16, with 2/31 (6.45%) stopping because of disease worsening and 3/31 (9.68%) withdrawing because of lack of efficacy.Table 3Adverse Events and Treatment Discontinuation at Week 16Patients (n = 31)Reported SeverityAdverse events, n (%) Acne2 (6.45)Mild Facial allergic dermatitis1 (3.23)Mild Fever2 (6.45)Mild Fatigue1 (3.23)MildTreatment discontinuation, n (%) Adverse event0Not applicable Disease worsening2 (6.45)Not applicable Lack of response3 (9.68)Not applicableNotes: Adverse-event severity was recorded descriptively; all reported adverse events were mild. Table 3Adverse Events and Treatment Discontinuation at Week 16Patients (n = 31)Reported SeverityAdverse events, n (%) Acne2 (6.45)Mild Facial allergic dermatitis1 (3.23)Mild Fever2 (6.45)Mild Fatigue1 (3.23)MildTreatment discontinuation, n (%) Adverse event0Not applicable Disease worsening2 (6.45)Not applicable Lack of response3 (9.68)Not applicableNotes: Adverse-event severity was recorded descriptively; all reported adverse events were mild. Adverse Events and Treatment Discontinuation at Week 16 Notes: Adverse-event severity was recorded descriptively; all reported adverse events were mild. Predictors of Clinical Response at Week 16 Univariate and multivariate logistic regression analyses were conducted to explore potential clinical and laboratory predictors of HiSCR achievement after 16 weeks of secukinumab treatment (Table 4). In the univariate analysis, no statistically significant differences were observed between HiSCR responders and non-responders in age, sex distribution, BMI, family history of HS, disease duration, baseline IHS4 score, smoking status, elevated white blood cell count, decreased HDL-C, or dyslipidemia (all p > 0.05). Prior biologic medication use showed a marginal trend toward a higher rate of HiSCR achievement (p = 0.094).Table 4Exploratory Univariate and Multivariable Analyses of Factors Associated with Achieving HiSCR at week 16 of Secukinumab TreatmentUnivariate AnalysisMultivariate AnalysisHiSCR Yesn =17HiSCR Non = 14P valueBetaP valueAge (years)25.59 (9.75)27.64 (11.43)0.597Gender (female)23.5% (4/17)21.4% (3/14)1.00BMI (kg/m2)28.10 (4.42)29.21 (3.83)0.544Family history (yes)17.6% (3/17)7.1% (1/14)0.607Disease duration7.76 (7.23)7.07 (4.16)0.570IHS4 baseline20.47 (16.00)29.14 (21.66)0.230Smoking (yes)41.2% (7/17)50.0% (7/14)0.725Previous utilization of biologic medications (yes)35.3% (6/17)7.1% (1/14)0.0943.1650.052Elevated WBC count (yes)58.8% (10/17)61.5% (8/13)1.000Decreased HDL-C (yes)29.4% (5/17)58.3% (7/12)0.148−0.9730.544Elevated TG (yes)29.4% (5/17)8.3% (1/12)0.3543.2460.037Dyslipidemia (yes)47.1% (8/17)75.0% (9/12)0.251−2.1040.193Notes: For laboratory variables, denominators vary owing to missing data; percentages were calculated using the available cases.Abbreviations: BMI, Body Mass Index; IHS4, International Hidradenitis Suppurativa Severity Scoring System; HiSCR, Hidradenitis Suppurativa Clinical Response; WBC, White Blood Cells; HDL-C, High-Density Lipoprotein Cholesterol; TG, Triglyceride. Table 4Exploratory Univariate and Multivariable Analyses of Factors Associated with Achieving HiSCR at week 16 of Secukinumab TreatmentUnivariate AnalysisMultivariate AnalysisHiSCR Yesn =17HiSCR Non = 14P valueBetaP valueAge (years)25.59 (9.75)27.64 (11.43)0.597Gender (female)23.5% (4/17)21.4% (3/14)1.00BMI (kg/m2)28.10 (4.42)29.21 (3.83)0.544Family history (yes)17.6% (3/17)7.1% (1/14)0.607Disease duration7.76 (7.23)7.07 (4.16)0.570IHS4 baseline20.47 (16.00)29.14 (21.66)0.230Smoking (yes)41.2% (7/17)50.0% (7/14)0.725Previous utilization of biologic medications (yes)35.3% (6/17)7.1% (1/14)0.0943.1650.052Elevated WBC count (yes)58.8% (10/17)61.5% (8/13)1.000Decreased HDL-C (yes)29.4% (5/17)58.3% (7/12)0.148−0.9730.544Elevated TG (yes)29.4% (5/17)8.3% (1/12)0.3543.2460.037Dyslipidemia (yes)47.1% (8/17)75.0% (9/12)0.251−2.1040.193Notes: For laboratory variables, denominators vary owing to missing data; percentages were calculated using the available cases.Abbreviations: BMI, Body Mass Index; IHS4, International Hidradenitis Suppurativa Severity Scoring System; HiSCR, Hidradenitis Suppurativa Clinical Response; WBC, White Blood Cells; HDL-C, High-Density Lipoprotein Cholesterol; TG, Triglyceride. Exploratory Univariate and Multivariable Analyses of Factors Associated with Achieving HiSCR at week 16 of Secukinumab Treatment Notes: For laboratory variables, denominators vary owing to missing data; percentages were calculated using the available cases. Abbreviations: BMI, Body Mass Index; IHS4, International Hidradenitis Suppurativa Severity Scoring System; HiSCR, Hidradenitis Suppurativa Clinical Response; WBC, White Blood Cells; HDL-C, High-Density Lipoprotein Cholesterol; TG, Triglyceride. The exploratory multivariable logistic regression model included elevated triglyceride, prior biologic medication use, decreased HDL-C, and dyslipidemia. Prior biologic medication use showed borderline evidence of association with HiSCR at week 16 (β = 3.165, p = 0.052). Elevated triglyceride was associated with HiSCR achievement in this model (β = 3.246, p = 0.037), whereas decreased HDL-C (β = −0.973, p = 0.544) and dyslipidemia (β = −2.104, p = 0.193) were not. Because the estimate was derived from a small cohort with few outcome events and incomplete lipid data, it should be interpreted as a hypothesis-generating association rather than as evidence of a validated prognostic biomarker. Discussion In this single-center prospective cohort of Chinese patients with moderate-to-severe HS, secukinumab-containing treatment regimens were associated with clinically meaningful improvement at week 16. The week 16 HiSCR rate was 54.8%, accompanied by significant reductions in inflammatory nodules, draining tunnels, IHS4, and DLQI. These findings are important because the cohort had a high inflammatory and structural disease burden; most patients were male, 67.74% had Hurley stage III disease, the mean disease duration was 7.45 years, and the baseline mean IHS4 was 24.39. Therefore, the observed response supports the effectiveness of IL-17A blockade in a real-world Chinese population in which advanced disease and long-standing tunnels are common. The response rate was within the range reported previously. For instance, in the pivotal SUNSHINE and SUNRISE phase 3 trials, HiSCR at week 16 was achieved by approximately 42%–46% of patients treated with secukinumab, and the response was sustained through week 52.16 In the Spanish multicenter real-world study by Fernandez-Crehuet et al, 48.9% of the patients achieved HiSCR at week 16,17 while Haselgruber et al reported an HiSCR rate of 41.79% at 24 weeks and showed that a lower therapeutic burden was associated with a better response.18 Our response rate of 54.8% at week 16 is slightly higher than the response rates seen in these larger Western cohorts, despite the higher proportion of patients with Hurley stage III disease. However, this comparison should be interpreted cautiously. Unlike randomized controlled trials in which secukinumab was evaluated under more strictly controlled treatment conditions, the present study reflects real-world clinical practice, and 74.19% of patients received concomitant therapies, including systemic antibiotics, systemic retinoids, intralesional or procedural treatments, and limited surgery. Therefore, the observed clinical improvement should be interpreted as the response to real-world treatment regimens containing secukinumab rather than the direct effect of secukinumab monotherapy. Nevertheless, this feature also represents one of the practical strengths of the study. In real-world HS management, secukinumab is often not used in isolation, particularly in patients with advanced disease, recurrent suppuration, draining tunnels, or high inflammatory burden. Concomitant antibiotics may help control secondary bacterial colonization and acute inflammatory flares, retinoids may improve follicular occlusion and keratinization abnormalities, and procedural or surgical interventions may reduce abscesses or tunnel-related disease burden. Accordingly, our findings provide evidence for the 16-week effectiveness and tolerability of secukinumab-centered comprehensive treatment strategies in Chinese patients with moderate-to-severe HS, rather than proving that secukinumab alone accounts for all observed improvement. Real-world studies have reported heterogeneous HiSCR response rates to secukinumab, ranging from approximately 26% to 90%, with higher responses observed in some Asian cohorts and in studies incorporating surgical treatment.19–24,26,27 Taken together, these data suggest that secukinumab efficacy is reproducible, but the observed response rates are strongly shaped by disease chronicity, tunnel burden, biologic exposure, concomitant therapy, surgical management, and endpoint timing. Mechanistically, the benefit of secukinumab is biologically plausible because IL-17 signaling is central to HS inflammation. HS lesions are characterized by follicular occlusion, dysregulated keratinocyte differentiation, neutrophil-rich inflammation, macrophage activation, and amplified cytokine networks involving IL-1β, TNF-α, IL-23, and IL-17.1,5 IL-17A promotes neutrophil recruitment and activation, induces keratinocytes to produce antimicrobial peptides and inflammatory mediators, and helps maintain the self-amplifying inflammatory loop that drives abscess development and draining tunnels.1 By selectively neutralizing IL-17A, secukinumab may reduce neutrophilic inflammation, suppress keratinocyte-derived inflammatory signals, and partially restore epidermal homeostasis. Consistent with this model, Moon et al found that clinical improvement after secukinumab was accompanied by downregulation of transcriptomic signals related to neutrophil/macrophage activation, keratinocyte differentiation, antimicrobial peptides, and fatty acid metabolism, affecting genes such as LCN2, KRT7, S100A7, S100A8, and FABP5.23 The reductions in IHS4, the NRS score for pain, and DLQI observed in the present study therefore likely reflect not only lesion suppression, but also attenuation of the IL-17A-driven inflammatory microenvironment. Although pain NRS decreased numerically by 28.3% from baseline to week 16, the change did not reach statistical significance (P = 0.064). This may partly reflect the limited sample size and interindividual variability in subjective pain assessment. In addition, pain in HS may arise from both active inflammation and chronic structural lesions, such as draining tunnels and scarring, which may respond differently over a relatively short 16-week treatment period. Therefore, the absence of statistical significance should not necessarily be interpreted as an absence of symptomatic improvement. An exploratory finding of this study was a potential association between lipid metabolism-related parameters and treatment response. In the multivariate analysis, elevated triglyceride was independently associated with HiSCR achievement at week 16, whereas decreased HDL-C and the broader category of dyslipidemia were not independent predictors. This result should not be interpreted as suggesting that hypertriglyceridemia is beneficial. Rather, triglyceride elevation may identify a subgroup with a more inflammation-linked metabolic phenotype that remains responsive to IL-17A blockade. HS is strongly associated with metabolic syndrome, insulin resistance, obesity, and dyslipidemia. A recent meta-analysis found that patients with HS had significantly higher triglyceride and lower HDL-C than healthy controls, but there were no consistent differences in TC or LDL-C.7 Similarly, Ozkur et al reported higher triglyceride, fasting glucose, and insulin concentrations, as well as more common insulin resistance and metabolic syndrome, in patients with HS than in BMI-matched controls.10 These observations support the idea that triglyceride is a sensitive marker of systemic inflammatory–metabolic disturbance in HS. Several mechanisms may explain why baseline triglyceride elevation predicted secukinumab response in our cohort. Chronic inflammatory activity alters lipid and lipoprotein metabolism, including increased hepatic very-low-density lipoprotein production and reduced clearance of triglyceride-rich lipoproteins, thereby contributing to a pro-atherogenic lipid pattern characterized by elevated triglyceride and reduced HDL-C.31,32 At the same time, adipose tissue is an active immune organ, and obesity-related cytokine production can interact with the TNF-α, IL-1β, and IL-17 pathways.1,5 Therefore, elevated triglyceride may capture the intersection between cutaneous inflammation and systemic metabolic inflammation more specifically than a composite dyslipidemia variable. This interpretation is consistent with real-world observations that biologic responders may show parallel improvement in clinical severity and lipid profiles, although lipid reductions have not always reached statistical significance.31 In practice, baseline triglyceride may represent a potential candidate marker for further investigation, but it requires validation in larger cohorts with fasting lipid measurements, insulin resistance indices, inflammatory markers, and longitudinal lipid follow-up. This study has some important limitations. The sample size was small, follow-up was limited to 16 weeks, and there was no placebo or active comparator group. The cohort also included patients treated with concomitant antibiotics, retinoids, or surgical intervention, which may have contributed to clinical improvement. In addition, the association analysis was exploratory and may be vulnerable to overfitting; the positive triglyceride signal should therefore be treated as hypothesis-generating rather than definitive. Future multicenter studies in the Chinese population should extend follow-up to 52 weeks, compare dosing intervals and combination strategies, and integrate clinical variables with lipidomics, transcriptomics, and inflammatory biomarkers to determine whether triglyceride elevation is a reproducible predictor of IL-17A inhibitor response in HS. Conclusions In this single-center prospective cohort, secukinumab demonstrated meaningful 16-week clinical benefit and a favorable safety profile in Chinese patients with moderate-to-severe HS, including a high proportion of patients with Hurley stage III disease. After 16 weeks, patients showed significant reductions in inflammatory nodules, draining tunnels, IHS4 score, and DLQI, with more than half achieving HiSCR. Notably, elevated baseline triglyceride showed an exploratory association with HiSCR achievement, suggesting a possible link between metabolic-inflammatory characteristics and treatment response. Larger multicenter studies with longer observation, standardized metabolic assessment, and integrated inflammatory or molecular biomarkers are needed to confirm the durability of secukinumab response and validate triglyceride elevation as a potential predictor of treatment outcomes in HS.